Pharmaceutical Executive: October 2024

Click the title above for a link to open the Pharmaceutical Executive October 2024 issue in an interactive PDF format.

Highlighting two pieces beyond Pharm Exec's October headliners that draw interesting parallels when it comes to life sciences leadership and building teams and capability internally—whether new businesses or new brands.

Industry leaders gather to discuss different ways life sciences organizations can champion their environmentally-conscious younger employees while combatting still-entrenched public mistrust.

As the overall industry pipeline of allogeneic T-cell therapies expands, the onus on manufacturers and their partners to adeptly manage the complex cryogenic logistics process intensifies.

The Big Pharma commercialization playbook doesn’t work for emerging life sciences companies bootstrapping their way up. Exploring three strategies that could be the ingredients of a winning formula for startups.

Rafaat Rahmani, president and founder of Lifescience Dynamics, grew up in abject poverty, but such hardships—and a later violent brush with racism—would ultimately end up fueling a determined and entrepreneurial path in the life sciences.

Practical ways product teams can leverage the benefits of generative artificial intelligence as a strategic advantage in pharmaceutical and life sciences commercialization.

Three key components to scaling quickly—while maintaining purpose.

Announcements such as Apple’s come with pros and cons for industry.

A value deficit and potential consumer value proposition.